Mechanism of ETI Therapy for Cystic Fibrosis N1303K Variant
发布者：Unknown
·发布于: 2025-12-13
A discussion on how the triple combination therapy (Elexacaftor + Tezacaftor + Ivacaftor) restores CFTR function in patients with the N1303K variant, specifically analyzing results from intestinal organoid swelling, intestinal current measurements, and clinical parameters.